OptimizeRx Corp 10-Q

Item 1. Financial Statements Our condensed consolidated financial statements included in this Form 10-Q are as follows: 2 Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 (unaudited); 3 Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 (unaudited); 4 Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months March 31, 2024 and 2023 (unaudited); 6 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (unaudited); 7 Notes to Condensed Consolidated Financial Statements (unaudited). 1 OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) (UNAUDITED) March 31, 2024 December 31, 2023 ASSETS Current assets Cash and cash equivalents $ 15,177 $ 13,852 Accounts receivable, net of allowance for credit losses of $ 371 and $ 480 at March 31, 2024 and December 31, 2023, respectively 29,748 36,253 Taxes receivable 1,036 1,036 Prepaid expenses and other 2,390 3,190 Total current assets 48,351 54,331 Property and equipment, net 153 149 Other assets Goodwill 78,357 78,357 Other intangibles, net 14,882 15,198 Tradename and customer relationships, net 33,596 34,198 Operating lease right of use assets, net 527 573 Security deposits and other assets 501 568 Total other assets 127,863 128,894 TOTAL ASSETS $ 176,367 $ 183,374 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Current portion of long-term debt $ 3,500 $ 2,000 Accounts payable – trade 1,665 2,227 Accrued expenses 7,278 7,706 Revenue share payable 2,814 5,506 Taxes payable 371 49 Current portion of lease liabilities 233 222 Deferred revenue 904 172 Total current liabilities 16,765 17,882 Non-current liabilities Long-term debt, net 32,413 34,231 Lease liabilities, net of current portion 314 371 Deferred tax liabilities, net 4,337 4,337 Total liabilities 53,829 56,821 Commitments and contingencies (See note 10) Stockholders’ equity Preferred stock, $ 0.001 par value, 10,000,000 shares authorized, none issued and outstanding at March 31, 2024 or December 31, 2023 — — Common stock, $ 0.001 par value, 166,666,667 shares authorized, 19,921,879 and 19,899,679 shares issued at March 31, 2024 and December 31, 2023, respectively 20 20 Treasury stock, $ 0.001 par value, 1,741,397 shares held at March 31, 2024 and December 31, 2023 ( 2 ) ( 2 ) Additional paid-in-capital 193,677 190,793 Accumulated deficit ( 71,157 ) ( 64,258 ) Total stockholders’ equity 122,538 126,553 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 176,367 $ 183,374 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (UNAUDITED) For the Three Months Ended March 31, 2024 2023 Net revenue $ 19,690 $ 13,003 Cost of revenues, exclusive of depreciation and amortization presented separately below 7,486 5,570 Gross profit 12,204 7,433 Operating expenses General and administrative expenses 16,166 14,032 Depreciation and amortization 1,067 464 Total operating expenses 17,233 14,496 Loss from operations ( 5,029 ) ( 7,063 ) Other income (expense) Interest expense ( 1,546 ) — Interest income 20 665 Total other income (expense), net ( 1,526 ) 665 Loss before provision for income taxes ( 6,555 ) ( 6,398 ) Provision for income taxes ( 344 ) — Net loss $ ( 6,899 ) $ ( 6,398 ) Weighted average number of shares outstanding – basic 18,170,108 17,094,676 Weighted average number of shares outstanding – diluted 18,170,108 17,094,676 Loss per share – basic $ ( 0.38 ) $ ( 0.37 ) Loss per share – diluted $ ( 0.38 ) $ ( 0.37 ) The accompanying notes are an integral part of these condensed consolidated financial statements. 3 OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY FOR THE THREE MONTHS ENDED MARCH 31, 2024 (in thousands, except share data) (UNAUDITED) Common Stock Treasury Stock Additional Paid in Accumulated Shares Amount Shares Amount Capital Deficit Total Balance January 1, 2024 19,899,679 $ 20 ( 1,741,397 ) $ ( 2 ) $ 190,793 $ ( 64,258 ) $ 126,553 Stock based compensation expense Options — — — — 1,353 — 1,353 Restricted stock — — — — 1,671 — 1,671 Issuance of common stock For options exercised — — — — — — — For restricted stock units vested 22,200 — — — ( 140 ) — ( 140 ) Net loss — — — — — ( 6,899 ) ( 6,899 ) Balance March 31, 2024 19,921,879 $ 20 ( 1,741,397 ) $ ( 2 ) $ 193,677 $ ( 71,157 ) $ 122,538 4 OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY FOR THE THREE MONTHS ENDED MARCH 31, 2023 (in thousands, except share data) (UNAUDITED) Common Stock Treasury Stock Additional Paid in Accumulated Shares Amount Shares Amount Capital Deficit Total Balance January 1, 2023 18,288,571 $ 18 ( 1,214,398 ) $ ( 1 ) $ 172,786 $ ( 46,692 ) $ 126,111 Stock based compensation expense Options — — — — 1,467 — 1,467 Restricted stock — — — — 2,914 — 2,914 Issuance of common stock For options exercised 9,668 — — — 40 — 40 For restricted stock units vested 33,272 — — — ( 171 ) — ( 171 ) Net loss — — — — — ( 6,398 ) ( 6,398 ) Balance March 31, 2023 18,331,511 $ 18 ( 1,214,398 ) $ ( 1 ) $ 177,036 $ ( 53,090 ) $ 123,963 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (UNAUDITED) For the Three Months Ended March 31, 2024 2023 OPERATING ACTIVITIES: Net loss $ ( 6,899 ) $ ( 6,398 ) Adjustments to reconcile net loss to net cash provided by (used in) provided by operating activities: Depreciation and amortization 1,067 464 Stock-based compensation 3,024 4,381 Bad debt expense 132 128 Amortization of debt issuance costs 182 — Changes in: Accounts receivable 6,373 3,862 Prepaid expenses and other assets 800 ( 1,734 ) Accounts payable ( 562 ) ( 261 ) Revenue share payable ( 2,692 ) ( 623 ) Accrued expenses and other liabilities ( 362 ) ( 476 ) Taxes payable 323 — Deferred revenue 732 571 NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 2,118 ( 86 ) INVESTING ACTIVITIES: Purchase of property and equipment ( 32 ) ( 29 ) Purchases of held-to-maturity investments — ( 56,927 ) Redemptions of held-to-maturity investments — 55,600 Capitalized software development costs ( 121 ) ( 194 ) NET CASH USED IN INVESTING ACTIVITIES ( 153 ) ( 1,550 ) FINANCING ACTIVITIES: Cash paid for employee withholding taxes related to the vesting of restricted stock units ( 140 ) ( 171 ) Proceeds from exercise of stock options — 40 Repayment of long-term debt ( 500 ) — NET CASH USED IN FINANCING ACTIVITIES ( 640 ) ( 131 ) NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 1,325 ( 1,767 ) CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 13,852 18,210 CASH AND CASH EQUIVALENTS - END OF PERIOD $ 15,177 $ 16,441 SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest $ 1,350 $ — Cash paid for income taxes $ 21 $ — The accompanying notes are an integral part of these condensed consolidated financial statements. 6 OPTIMIZERX CORPORATION NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, excepts share and per share data) (UNAUDITED) NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION The accompanying condensed consolidated financial statements include OptimizeRx Corporation and its wholly owned subsidiaries (collectively, the “Company”, “we”, “our”, or “us”). We are a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over two million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary point-of-care network, as well as mass digital communications channels, OptimizeRx helps life sciences organizations engage and support their customers. The condensed consolidated financial statements for the three months ended March 31, 2024 and 2023 have been prepared by us without audit pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments necessary to present fairly our financial position at March 31, 2024, and our results of operations, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2024 and 2023, have been made. Those adjustments consist of normal and recurring adjustments. The condensed consolidated balance sheet as of December 31, 2023, has been derived from the audited consolidated condensed balance sheet as of that date. Certain information and note disclosures, including a detailed discussion about the Company’s significant accounting policies, normally included in our annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with a reading of the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on April 15, 2024 (“Form 10-K”). The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year. On October 24, 2023, the Company acquired 100 % of the issued and outstanding preferred and common stock of Healthy Offers, Inc., a Nevada corporation d/b/a Medicx Health (“Medicx Health”) - See Part II, Item 8. Financials Statements and Supplementary Data; Note 3 - Acquisitions in our Form 10-K for additional information regarding this transaction. The following presents the pro-forma consolidated statement of operations as if Medicx Health had been included in the consolidated results of the Company for the three months ended March 31, 2023: Pro-forma consolidated statement of operations Revenue $ 21,031 Net loss ( 8,632 ) These amounts have been calculated after applying the Company’s accounting policies, adjusting Medicx Health results to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied on January 1, 2023, interest expense associated with the term loan and elimination of interest income on short-term investments that were used to fund the acquisition. During the year ended December 31, 2023, the Company disposed of its non-core Access solutions - See Part II, Item 8. Financials Statements and Supplementary Data; Note 7 - Goodwill and Intangible Assets in our Form 10-K for additional information regarding this transaction. A pro-forma statement of operations for the three months ended March 31, 2023, is not presented for this transaction as the pro-forma impacts were not material to the Company’s consolidated results. The Revenue presented in the pro-forma financial consolidated statement of operations data above includes $ 1,876 related to Access and other non-core solutions for which no revenue was recorded in the three months ended March 31, 2024, (see also the discussion under Net Revenues in Results of Operations for the Three Months Ended March 31, 2024 and 2023 in Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations). NOTE 2 – NEW ACCOUNTING PRONOUNCEMENTS In November 2023, the FASB issued ASU No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09. 7 OPTIMIZERX CORPORATION NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, excepts share and per share data) (UNAUDITED) NOTE 3 – CAPITALIZED SOFTWARE COSTS The Company capitalizes certain development costs incurred in connection with software development for internal-use software platforms used in operations and for providing services to our customers. Costs incurred in the preliminary stages of development are expensed as incurred. Once software has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized internal use software development costs are included in intangible assets and are amortized on a straight-line basis over the estimated useful life of the software platforms and are included in depreciation and amortization within operating expenses in the consolidated statements of operations. Amortization of capitalized internal use software expense for the three months ended March 31, 2024 and 2023 was $ 71 and $ 48 , respectively. The Company accumulates capitalizable costs related to current projects in a construction in process (“CIP”) software account, the balance of which was $ 351 and $ 696 at March 31, 2024 and December 31, 2023, respectively. NOTE 4 – REVENUES Under ASC 606, Revenue from Contracts with Customers (“ASC Topic 606”), we record revenue when earned, rather than when billed. From time to time, we may record revenue based on our revenue recognition policies in advance of being able to invoice the customer, or we may invoice the customer prior to being able to recognize the revenue. Included in accounts receivable are unbilled amounts of $ 4,471 and $ 4,198 at March 31, 2024, and December 31, 2023, respectively. Amounts billed in advance of revenue recognition are presented as deferred revenue on the condensed consolidated balance sheets. Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of eprescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. This content delivery for a customer is referred to as a program. Unless otherwise specified, revenue is recognized based on the selling price to customers. The Company’s contracts are generally all less than one year and the primary performance obligation is delivery of messages, or content, but the contract may contain additional services. Additional services may include program design, which is the design of the content delivery program, set up, and reporting. We consider set up and reporting services to be complimentary to the primary performance obligation and recognized through performance of the delivery of content. We consider program design and related consulting services to be performance obligations separate from the delivery of messages. The net contract balance for contracts in progress at March 31, 2024 and December 31, 2023, was $ 33,568 and $ 2,021 , respectively. The outstanding performance obligations are expected to be satisfied during the year ended December 31, 2024. In certain circumstances, the Company will offer sales rebates to customers based on spend volume. Rebates are typically contracted based on a quarterly or annual spend amount based on a volume threshold or tiered model. At the beginning of the year, the rebate percentage is estimated based on input from the sales team and analysis of prior year sales. Thereafter, the open contract balance for the customer is assessed quarterly to ensure the estimated rebate percentage being used for the rebate accrual remains reasonable. The estimated amount of variable consideration will be included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For the year ended 2023 and during the first quarter of 2024, there were two contracts with customers that included a rebate clause. As the content is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized over time as the distributions occur. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance. This reporting revenue is recognized over time as the messages are delivered. Program design, which is the design of the content delivery program, and related consulting services are recognized as services are performed. In some instances, we also resell messaging solutions that are available through channel partners that are complementary to the core business and client base. These partner specific solutions are frequently similar to our own solutions and revenue recognition for these programs is the same as described above. In instances where we sell solutions on a commission basis, net revenue is recognized based on the commission-based revenue split that we receive. In instances where we resell these messaging solutions and have all financial risk and significant operation input and risk, we record the revenue based on the gross amount sold and the amount paid to the channel partner as a cost of sales. 8 OPTIMIZERX CORPORATION NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, excepts share and per share data) (UNAUDITED) NOTE 4 – REVENUES (CONTINUED) The Company has several signed contracts with customers for the distribution of messaging, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under its revenue recognition policy. Deferred revenue was $ 904 and $ 172 as of March 31, 2024 and December 31, 2023, respectively. The contracts are all short term in nature and all revenue is expected to be recognized within 12 months, or less. The following is a summary of activity for the deferred revenue account for the three months ended March 31: 2024 2023 Balance January 1 $ 172 $ 164 Revenue recognized ( 3,229 ) ( 2,444 ) Amount collected 3,961 3,015 Balance March 31 $ 904 $ 735 Disaggregation of Revenue Consistent with ASC Topic 606, we have disaggregated our revenue by timing of revenue recognition. The majority of our revenue is recognized over time as solutions are provided. A small portion of our revenue related to program development, solution architect design, and other solutions is recognized at a point in time upon delivery to customers. A break down is set forth in the table below. Three Months Ended March 31, 2024 2023 Revenue recognized over time $ 16,925 $ 12,573 Revenue recognized at a point in time 2,765 430 Total Revenue $ 19,690 $ 13,003 Accounts receivable are reported at realizable value, net of allowances for credit losses, which is estimated and recorded in the period the related revenue is recorded. The Company does not seek collateral to secure its accounts receivable and amounts billed are generally due within a short period of time based on terms and conditions normal for our industry. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Past-due receivable balances are written off when the Company’s collection efforts have been exhausted. The following is a summary of changes in the allowance for credit losses for the three months ended March 31,: 2024 2023 Balance at January 1, $ 239 $ 352 Bad debt expense 132 128 Write-offs — — Balance at March 31, $ 371 $ 480 9 OPTIMIZERX CORPORATION NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, excepts share and per share data) (UNAUDITED) NOTE 5 – LONG-TERM DEBT Long-term debt, net comprised the following at March 31, 2024 and December 31, 2023: March 31, 2024 December 31, 2023 Term loan, due in 2027 $ 37,790 $ 38,290 Less: current portion ( 3,500 ) ( 2,000 ) Less: unamortized issuance costs ( 1,877 ) ( 2,059 ) Long-term debt, net $ 32,413 $ 34,231 As of March 31, 2024, the Term loan bears interest at 14.1 %, with an effective rate of 16.0 %, including the impact of the amortization of debt issuance costs of $ 182 for the three months ended March 31, 2024. The Company was in full compliance with the financial covenants associated with the Term loan. The Term Loan is repayable in quarterly installments, beginning December 31, 2023, equivalent to 1.25 % or $ 500,000 , of the original principal amount, with the outstanding unpaid principal and all accrued but unpaid interest due and payable on the earlier of (i) the fourth anniversary of the closing date of the Term Loan or (ii) the date on which the Term Loan is declared due and payable pursuant to the terms of the Financing. In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00. Excess Cash Flow is defined in the Financing as Consolidated EBITDA for the previous fiscal year less scheduled principal and interest payments, capital expenditure, cash taxes and any cash expenses/gains added back to net income in the calculation of Consolidated EBITDA, adjusted for any increase/decrease in working capital during the fiscal year. Repayments due under the terms of the Term loan, including an estimate of the amount associated with the Excess Cash Flow calculation discussed above, for the remainder of the current and in each of the next three fiscal years are as follows: As of March 31, 2024 2024 (remainder) $ 1,500 2025 3,500 2026 2,000 2027 30,790 $ 37,790 NOTE 6 – LEASES We had operating leases with terms greater than 12 months for office space in four multi-tenant facilities, which are recorded as Operating lease right-of-use assets and Operating lease liabilities. For the three months ended March 31, 2024 and 2023, the Company’s lease cost consists of the following components, each of which is included in operating expenses within the Company’s condensed consolidated statements of operations: Three Months Ended March 31, 2024 2023 Operating lease cost $ 62 $ 25 Short-term lease cost 1 8 Total lease cost $ 63 $ 33 10 OPTIMIZERX CORPORATION NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, excepts share and per share data) (UNAUDITED) NOTE 6 – LEASES (CONTINUED) The table below presents the future minimum lease payments to be made under operating leases in each of the remainder of the current and next four fiscal years and thereafter: As of March 31, 2024 2024 (remainder) $ 196 2025 187 2026 114 2027 66 2028 45 Thereafter — Total 608 Less: discount 61 Total lease liabilities $ 547 The weighted average remaining lease term at March 31, 2024 for the operating lease is 3.0 years, and the weighted average discount rate used in calculating the operating lease asset and liability is 6.75 %. Cash paid for amounts included in the measurement of lease liabilities was $ 54 and $ 22 for the three months ended March 31, 2024 and 2023, respectively. For the three months ended March 31, 2024 and 2023, payments on lease obligations were $ 65 and $ 25 , respectively, and amortization on the right of use assets was $ 51 and $ 25 , respectively. NOTE 7 – STOCKHOLDERS’ EQUITY Preferred Stock The Company had 10,000,000 shares of preferred stock, $ 0.001 par value per share, authorized as of March 31, 2024. No shares were issued or outstanding in either 2024 or 2023. Common Stock The Company had 166,666,667 shares of common stock, $ 0.001 par value per share, authorized as of March 31, 2024. There were 18,180,482 and 18,158,282 shares of common stock outstanding, net of shares held in treasury of 1,741,397 and 1,741,397 at March 31, 2024 and December 31, 2023, respectively. During the three months ended March 31, 2024, the Company issued no shares of our common stock, and received no proceeds in connection with the exercise of options under our 2013 Incentive Plan and our 2021 Equity Incentive Plan. The Company issued 22,200 shares of common stock in the three months ended March 31, 2024, in connection with the vesting of restricted stock units under our 2013 Incentive Plan and our 2021 Equity Incentive Plan. Some of the participants utilized a net withhold settlement method, in which shares were surrendered to cover payroll withholding taxes. Of the shares issued to participants during the three months ended March 31, 2024, 9,423 shares, valued at $ 140 , were surrendered and subsequently cancelled. During the three months ended March 31, 2023, the Company issued 9,668 shares of our common stock and received proceeds of $ 40 , in connection with the exercise of options under our 2013 Incentive Plan. The Company issued 33,272 shares of common stock in the three months ended March 31, 2023, in connection with the vesting of restricted stock units under our 2013 Incentive Plan and our 2021 Equity Incentive Plan. 9,502 shares valued at $ 171 were surrendered in connection with the net withhold settlement method and were subsequently cancelled. 11 OPTIMIZERX CORPORATION NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, excepts share and per share data) (UNAUDITED) NOTE 7 – STOCKHOLDERS’ EQUITY (CONTINUED) Treasury Stock During the quarter ended March 31, 2023, the Board authorized a share repurchase program, under which the Company could repurchase up to $ 15.0 million of its outstanding common stock. This stock repurchase authorization expired on March 12, 2024. During each of the quarters ended March 31, 2024 and 2023 , the Company did not repurchase any of its outstanding shares of common stock. Stock Options The compensation expense related to options for the three months ended March 31, 2024 and 2023 was $ 1,353 and $ 1,467 , respectively. The fair value of these instruments was calculated using the Black-Scholes option pricing model. There is $ 7,479 of remaining expense related to unvested options to be recognized in the future over a weighted average period of 1.59 years. The total intrinsic value of outstanding options at March 31, 2024 was $ 492 . During 2023, the Company granted certain performance-based stock options, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was no expense related to these options recorded during the period. Restricted Stock Units The Company recorded $ 1,671 and $ 2,914 in compensation expense related to restricted stock units for the three months ended March 31, 2024 and 2023, respectively. A total of $ 9,967 remains to be recognized at March 31, 2024 over a weighted average period of 1.67 years. During 2022, the Company granted certain performance based restricted stock units, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was no expense related to these restricted stock units recorded during the period. The director’s compensation program calls for the grant of restricted stock units with a one year vesting period. There was $ 199 and $ 185 included in the compensation expense discussed above related to director’s compensation for the periods ended March 31, 2024 and 2023, respectively. NOTE 8 – LOSS PER SHARE Basic earnings per share (“EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. The number of shares related to options and restricted stock units included in diluted EPS is based on the “Treasury Stock Method” prescribed in ASC 260-10, Earnings per Share . This method assumes the theoretical repurchase of shares using proceeds of the respective stock options exercised, and for restricted stock units, the amount of compensation cost attributed to future services which have not yet been recognized, and the amount of current and deferred tax benefit, if any, that would be credited to additional paid in capital upon the vesting of the restricted stock units, at a price equal to the issuer’s average stock price during the related earnings period. Accordingly, the number of shares that could be included in the calculation of EPS in respect of the stock options and restricted stock units is dependent on this average stock price and will increase as the average stock price increases. 12 OPTIMIZERX CORPORATION NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, excepts share and per share data) (UNAUDITED) NOTE 8 – LOSS PER SHARE (CONTINUED) The following table sets forth the computation of basic and diluted net loss per share. Three Months Ended March 31, 2024 2023 Numerator Net loss $ ( 6,899 ) $ ( 6,398 ) Denominator Weighted average shares outstanding used in computing net loss per share Basic 18,170,108 17,094,676 Effect of dilutive stock options, warrants, and stock grants — — Diluted 18,170,108 17,094,676 Net loss per share Basic $ ( 0.38 ) $ ( 0.37 ) Diluted $ ( 0.38 ) $ ( 0.37 ) The number of common shares potentially issuable upon the exercise of certain options and the vesting of certain restricted stock units that were excluded from the diluted loss per common share calculation are reflected in the table below. Three Months Ended March 31, Weighted average number of shares for the periods ended 2024 2023 Options 22,522 34,055 Unvested restricted stock unit awards 83,237 59,749 Total 105,759 93,804 NOTE 9 – COMMITMENTS AND CONTINGENT LIABILITIES Litigation From time to time, the Company may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us. Commitments From time to time, the Company enters into arrangements with partners to acquire minimum amounts of media, data or messaging capabilities. As of March 31, 2023, the Company had commitments for future minimum payments of $ 22.6 million that will be reflected in cost of revenues during the years from 2024 through 2028. Minimum payments are due in the remainder of 2024 and fiscal 2025, 2026, 2027 and 2028 in the amounts of $ 8.5 million, $ 8.3 million, $ 3.3 million, $ 2.4 million and $ 0.1 million, respectively. NOTE 10 – INCOME TAXES The Company reported a provision for income taxes of $ 344 for the three months ended March 31, 2024, representing an effective tax rate of ( 5.2 )%. The effective tax rate for the three months ended March 31, 2024 reflects the impact of certain permanent items, projected increases in our valuation allowance during the year and discrete items for the quarter related to stock based compensation. There was no provision for or benefit from taxes in the three months ended March 31, 2023, as we carried a full valuation allowance against our net deferred tax assets due to our history of losses. As discussed in our annual report on Form 10-K for the year ended December 31, 2023, we had net operating loss carry-forwards for federal income tax purposes of approximately $ 16.7 million as of December 31, 2023. NOTE 11 – SUBSEQUENT EVENTS NONE 13